Freenome to present new validation data for next-generation CRC Screening Test in late-breaking oral presentation at ACG 2026. Published on 10/11/2026 at 01:00 pm EDT GlobeNewswire - Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention - - Overall detection of colorectal cancer remained consistent with test's first version, achieving 80.4% sensitivity at 90% specificity - BRISBANE, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) - Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the company will present late-breaking data on an updated version of its SimpleScreen(TM) CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville. Freenome conducted a pivotal clinical validation study to assess the performance of assay and algorithm improvements for the updated version of SimpleScreen CRC. The FDA approved the first-generation version of SimpleScreen CRC in July 2026, and the test was commercially launched in late September in the United States by Freenome's partner Abbott Cancer Diagnostics. The updated test demonstrated 18.2% sensitivity for detecting advanced precancerous lesions (APLs), a significant improvement compared to the 13.7% sensitivity in the original PREEMPT CRC(R) study.[1] Sensitivity for APLs with high-grade dysplasia (HGD) improved to 41.9% in the updated test, compared to 30.5% reported previously. The sensitivity results for APLs and APLs with HGD demonstrated in this study are the highest reported to date for any non-invasive screening blood test in a prospective registrational pivotal clinical study. Sensitivity was also improved for all APL subtypes, including villous or tubulovillous; adenomas >= 10 mm; sessile serrated lesions/polyps >= 10 mm; and traditional serrated adenomas. Overall, 80.4% sensitivity was demonstrated for detecting CRC. The results were adjusted to the age and sex distribution of the U.S. Census to better reflect the intended use population, and specificity for no findings on colonoscopy was 90%. "These results suggest that our blood-based screening test may detect precancerous lesions with clinically meaningful sensitivity," said Aaron Elliott, Ph.D., CEO of Freenome. "The ability to continually improve performance through refinements to our assay and algorithm, as seen with these results, is a fundamental part of our up-versioning strategy. We believe this iterative methodology not only improves CRC APL performance but is also applicable across our multi-cancer pipeline. Combined with our personalized cancer detection approach, this is how we continue to expand blood-based screening into an accessible option for the millions of Americans who remain unscreened." Aasma Shaukat, M.D., M.P.H., professor of medicine at NYU Grossman School of Medicine and a co-lead principal investigator on the PREEMPT CRC study, will present the detailed results. Presentation title: Improved Sensitivity for Advanced Precancerous Lesions (APLs) Demonstrated in Clinical Validation of an Updated Colorectal Cancer (CRC) Screening Blood Test in an Average-Risk Population. Date: Wednesday, Oct. 14 Time: 9:10-9:20 am Session: Plenary Session 4B: Liver, Esophagus, CRC, IBD About Freenome Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen(TM) CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com. Forward-Looking Statements Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will" and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are making this statement for purposes of complying with those safe harbor provisions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding SimpleScreen CRC's impact and ability to reach additional patients; the impact of FDA approval including with respect to Medicare and ACS guidelines; Freenome's partnership with Abbott and the expected results and benefits thereof; and Freenome's business and strategy, including its plans with respect to its broader SimpleScreen portfolio and multiomics platform. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks related to the approval of Freenome's products and tests and the timing of expected regulatory and business milestones; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive products and tests; ability to obtain sufficient supply of materials; ability to obtain additional financing; ability to attract and retain qualified personnel; global economic and political conditions; legal and regulatory changes; the outcome of any legal proceedings that may be instituted against Freenome; the effects of competition on Freenome's future business; as well as those set forth in Freenome's most recent filings with the SEC, including our Form S-1. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. References 1. Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA. Published online June 2, 2025. doi: 10.1001/jama.2025.7515. Media contact Ryan Flinn The Grace Group [email protected] Investor contact [email protected] (C) GlobeNewswire - 2026

AI-Powered Liquid Biopsy emerges as a high-stakes frontier in precision oncology, attracting hundreds of millions in venture and public funding. "BCC Research examines how AI is improving biomarker detection, ctDNA analysis, early cancer diagnosis and disease monitoring while advancing precision oncology and clinical decision-making." September 29, 2026 08:23 ET | Source: BCC Research LLC Boston, Sept. 29, 2026 (GLOBE NEWSWIRE) - Artificial intelligence is fundamentally reshaping the liquid biopsy landscape, transforming blood-based cancer diagnostics from a promising concept into a clinically deployable, commercially scalable precision oncology tool. BCC Research's latest analysis, AI Impact on Liquid Biopsy with Emphasis on Cancer Market - BCC Pulse Report, examines the accelerating convergence of AI, multiomics, and noninvasive diagnostics, mapping the investment flows, technological advances, and strategic partnerships defining this rapidly evolving space. Key Findings - Surging Investment Activity: AI-driven liquid biopsy platforms have attracted substantial capital across funding rounds and public programs. Freenome secured $254 million in 2024 - led by Roche - to advance its multiomics platform integrating cfDNA, protein, and RNA for multicancer detection. The European Investment Bank committed approximately $23 million to Universal DX in 2025, while ARPA-H selected Tempus AI for its ADAPT program targeting metastatic cancers using AI-driven biomarker and clinical trial design frameworks. - AI Adoption Concentrated in High-Value Use Cases: Current AI integration is most prominent in early cancer detection, biomarker discovery, and therapy monitoring - precisely those applications where complex multiomic data volumes exceed the analytical capacity of conventional methods and where diagnostic accuracy directly impacts patient outcomes. - Multiomics Integration as the Central Technical Driver: AI's capacity to simultaneously analyze cfDNA, RNA, protein, epigenetic, and fragmentomic data from a single blood draw is enabling multicancer detection from one sample - a capability that fundamentally expands the clinical addressability and commercial scope of liquid biopsy platforms. - Public-Sector Programs Accelerating Clinical Validation: Government funding is de-risking the clinical validation pipeline. ARPA-H's ADAPT initiative, NIH's Cancer Moonshot, and EU consortium programs such as BRECISE - which provided approximately $2.1 million to Novigenix AI in 2025 - are embedding AI-enabled liquid biopsy into real-world oncology workflows and regulatory pathways. - Emerging Technologies Deepening the Diagnostic Stack: Key technology frontiers include foundation models and deep learning for cfDNA methylation analysis, exosome-based biopsy combined with AI and Raman spectroscopy, infrared spectroscopy with PANOmics platforms, and paper-based AI liquid biopsy systems designed for resource-constrained settings. Freenome's 2026 collaboration with NVIDIA to develop an open-source cfDNA methylation foundation model signals growing infrastructure-level commitment to the space. - Competitive Landscape: Leading players include Guardant Health, GRAIL, Freenome, Natera, SOPHiA GENETICS, Illumina, Roche, QIAGEN, and Tempus AI, alongside emerging innovators such as OneCell Diagnostics, Dxcover, Oxford Cancer Analytics, Tvaster Genkalp, Universal DX, Novigenix AI, Gene Solutions, PanGIA Biotech, Zephyr AI, and M42. Strategic Implications Rising global cancer incidence, combined with strong clinician and patient preference for noninvasive testing, is generating sustained structural demand for AI-enhanced liquid biopsy platforms. Blood-based diagnostics that previously lacked clinical-grade sensitivity are being repositioned as viable alternatives to tissue biopsy - a shift enabled directly by AI's ability to extract signal from low-frequency tumor variants and complex biological noise in cfDNA and exosome data. Platform partnerships are accelerating this transition. Guardant Health's 2025 integration with Zephyr AI for multimodal biomarker discovery, Illumina's 2026 launch of Connected Multiomics, and Roche's deployment of a large-scale NVIDIA GPU-powered AI factory all reflect a broader infrastructure buildout that will lower the cost and time required to bring the next generation of diagnostics to clinical scale. Academic anchors including Johns Hopkins University and Stanford University are simultaneously advancing large-scale data modeling, reinforcing the scientific credibility underpinning commercial platforms. Investment Considerations The AI-driven liquid biopsy sector presents a differentiated investment opportunity at the intersection of oncology, diagnostics, and applied AI. Established players such as Roche, Illumina, and Natera - which launched proprietary AI foundation models in 2025 - are building scalable platform advantages, while well-capitalized startups such as Freenome and OneCell Diagnostics are positioned as both innovation drivers and acquisition targets. Investors should weigh meaningful near-term headwinds: regulatory approval timelines, GDPR-constrained data aggregation in Europe, limited reimbursement infrastructure in developing markets, and the biological complexity of isolating tumor-derived signals from exosomal noise. Nonetheless, the convergence of public funding mandates, VC conviction, and expanding clinical partnerships suggests that market leadership in this segment will be determined over the next three to five years - rewarding early, well-positioned capital. About the Report AI Impact on Liquid Biopsy with Emphasis on Cancer Market - BCC Pulse Report provides qualitative strategic analysis covering the AI technology landscape in liquid biopsy, investment and funding activity, key use case adoption, emerging technology assessment, competitive intelligence, and profiles of leading and emerging market participants. About BCC Research BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Jefferies initiated coverage of Freenome with a Buy rating and $17 price target on 17 August 2026, according to CNBC. The target implies a roughly 47% increase from the previous close of $11.56. Shares jumped more than 12% on the news. Freenome develops blood-based cancer screening tests. The company recently went public via a SPAC merger on 21 July 2026, raising more than $300 million. Its lead product, a colorectal cancer test, won FDA approval on 27 July 2026. Abbott Laboratories handles US commercialisation under a deal that included a $100 million milestone payment. Roche covers international markets and led a $254 million funding round in 2024. The company plans to expand into lung cancer screening and aims to cover more than ten cancer types over time.